Posts in: investor

Perriman at Nasdaq
investornutraceuticalsmedicinepress clippingsvideo
Nasdaq: Damien Perriman interview on NCTApril 2, 2026
Transcript: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026
investor
Transcript: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026April 1, 2026
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
press releaseinvestor
eXoZymes Provides Fourth Quarter and Full Year 2025 UpdateMarch 31, 2026
Q4 + 2025 investor call
investor
Sign up: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026March 25, 2026
eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
investornutraceuticalsmedicine
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade outputMarch 18, 2026
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026
investorpress clippingsvideo
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026February 16, 2026
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
press releaseinvestor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creationFebruary 10, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
yahoo! finance
investorpress clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated productJanuary 30, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
Previous page
Page 1 of 8
Next page